Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The POUR Study: Sugammadex for Urinary Retention in Hernia Repair
NCT05276804Phase 3Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Apr 2022
- Primary completion
- Sep 2024
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Sugammadex in postoperative urinary retention (POUR), sponsored by Wake Forest University Health Sciences. Started Apr 2022; status: completed.
02
Drugs
Sugammadex
03
Conditions
postoperative urinary retention (POUR)
Beyond the preview
Go deeper on NCT05276804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05276804.